NJ Biopharmaceuticals, a leading provider of chemistry and biopharmaceutical services specialising in bioconjugation, custom synthesis, fl ow chemistry, and process development has expanded its footprint at its laboratory and headquarters at Princeton, New Jersey (USA) from 35,000 square feet to approximately 79,000 square feet. The expansion will include GMP manufacturing capabilities for bioconjugates and small molecules. With the expansion, NJ Bio will soon be able to support the development and GMP manufacturing of Antibody Drug Conjugates (ADCs) to meet the growing demand for clinical assets in this fi eld. NJ Bio is aggressively hiring synthetic organic, bioconjugation and oligonucleotide chemists as well as analytical and QA/QC personnel to increase capacity and build up its GMP manufacturing capabilities.
NJ Bio will also continue to operate its facility in Bristol (Pennsylvania, USA) with plans to further expand its GMP manufacturing capabilities. Commenting on the development, Dr. Nareshkumar Jain, President and CEO of NJ Bio, said, “We are laser-focused on setting up our state-of-theart GMP manufacturing suites to become operational in 2022.
This expansion will enable us to manufacture GMP grade payload-linkers, drug candidates, and antibody-drug conjugates for phase 1-3 clinical studies for our clients.” The company said the expansion of resources and facilities is an important step to transition from being a contract research provider to a contract development and manufacturing organisation (CDMO).
No comments:
Post a Comment